GlassScriptPhysician profile
Dana B Mather
NPI 1689794257
$8,374.70
in general payments reported to CMS, 2019-2025
28 companies · $2,190 in 2025
The $2,190 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,279 · 2022: $1,214 · 2023: $1,812 · 2024: $1,879 · 2025: $2,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,822 · Consulting Fee: $59.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,822.17 |
| Consulting Fee | $59.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,322.95 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $1,040.50 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $855.11 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $837.62 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Grifols USA, LLC | $688.50 | 2022-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $589.19 | 2021-2025 | Hyqvia, Takhzyro, Cuvitru |
| Regeneron Healthcare Solutions, INC. | $511.56 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $467.23 | 2021-2025 | |
| Blueprint Medicines Corporation | $405.96 | 2021-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $337.51 | 2021-2025 | Orladeyo |
| Amgen INC. | $196.40 | 2021-2025 | Tezspire |
| Pharming Healthcare, INC. | $182.10 | 2021-2025 | Ruconest |
| Genentech USA, INC. | $124.06 | 2023-2024 | Xolair |
| Kaleo, INC. | $108.28 | 2021-2024 | Auvi-Q |
| Pfizer INC. | $90.65 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $86.76 | 2021-2024 | Immunocap |
| Abbvie INC. | $86.51 | 2022-2023 | |
| Octapharma USA, INC. | $75.31 | 2021 | |
| Optinose US, INC. | $68.50 | 2021-2025 | |
| Adma Biomanufacturing LLC | $59.91 | 2023-2025 | |
| Bio Products Laboratory USA, INC. | $58.41 | 2022-2023 | Gammaplex, Coagadex |
| Ionis Pharmaceuticals, INC. | $47.52 | 2025 | Dawnzera |
| Boston Scientific Corporation | $36.16 | 2022-2025 | General - Pain Management |
| Redhill Biopharma INC. | $27.71 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $22.36 | 2025 | Neffy |
| Gc Biopharma USA, INC. | $18.01 | 2024 | Alyglo |
| Cycle Pharmaceuticals INC | $16.04 | 2025 | Sajazir |
| Eyevance Pharmaceuticals LLC | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Mather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.